Hosted on MSN1mon
GSK raises long-term guidance, announces buybacks
The company ... GSK’s (NYSE:GSK) new vaccine for respiratory syncytial virus (RSV) and Shingrix, its shingles vaccine, fell ~69% YoY and ~4% YoY. Meanwhile, GSK’s (NYSE:GSK) full-year revenue ...
Morningstar25d
PENMENVY, GSK’s 5-in-1 Meningococcal Vaccine, Approved by US FDA to Help Protect Against MenABCWY
Please consult the full Prescribing Information for additional safety information GSK is a global biopharma company with a purpose ... in GSK’s Annual Report on Form 20-F for 2023, and GSK ...
Longview News-Journal24d
GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit with the Schall Law Firm
reminds investors of a class action lawsuit against GSK plc ("GSK" or "the Company") (NYSE: GSK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 ...
Pharmabiz17d
GSK completes acquisition of Boston-based, clinical-stage biopharma company, IDRx, Inc.
GSK plc announced that it has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based, clinical-stage biopharmaceutical company dedicated to developing ... GIST represent the most prevalent ...